Erythropoietin and Diabetic Retinopathy
- *Corresponding Author:
- Anna Cancarini
Department of Ophthalmology
University of Brescia, Brescia, Italy
Postal address: P.leSpedaliCivili 1
25123 Brescia, Italy
E-mail: [email protected]
Received date: July 25, 2013; Accepted date: August 17, 2013; Published date: August 23, 2013
Citation: Semeraro F, Cancarini A, Forbice E, Morescalchi F, Donati S, et al. (2013) Erythropoietin and Diabetic Retinopathy. J Diabetes Metab 4:283. doi: 10.4172/2155-6156.1000283
Copyright: © 2013 Semeraro F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Diabetic retinopathy (DR) is the main cause of visual impairment in industrialized countries. Great efforts are in place to search for new therapies able to prevent the development of DR and the onset of its complications. At present, therapy consists of anti-VEGF intra vitreal injections and is aimed at preventing the main causes of visual impairment, that is, macular oedema and retinal proliferation. However, the current knowledge has led us to hypothesize about the roles of other factors implicated in the pathogenesis of macular oedema and retinal proliferation; erythropoietin (EPO) is one such compound.
The aim of the work was to review the recent literature on the applications of EPO within the context of DR etiopathogenicity.